(firstQuint)Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001.

 Complying with requirements of the approval letter of clinical trial issued by SFDA (Approval Letter No.

: 2006L01017), Hualan conducted phase I clinical trial of Group ACYW135 Meningococcal Polysaccharide Vaccine.

 The safety end points were the presence of any systemic, local and adverse reaction.

.

 Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001@highlight

The clinical trial was designed to evaluate the safety against Group ACYW135 Meningococcal Polysaccharide Vaccine of Hualan administered on subjects 2 years of age and older.

